Streetbeat News

Stock Prices

SSBK

Southern States (NASDAQ:SSBK) reported Q3 earnings of $1.06 per share, beating the analyst consensus estimate of $0.74 by 43.24%. This is a 37.66% increase from the same period last year. However, the company reported quarterly sales of $17.84 million, missing the analyst consensus estimate of $20.30 million by 12.13%. This is a 14.14% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:36 am

FMC

FMC Corporation has updated its Q3 expectations and 2023 outlook, stating that its Q3 revenue and earnings outlook has been reduced primarily due to lower volumes in Latin America as destocking was more severe than anticipated.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:34 am

AKU

HARP

LMDX

ROIV

TGH

TRKA

XRTX

The article lists the top gainers and losers in pre-market trading. LumiraDx Limited's shares surged after a strategic collaboration with AstraZeneca and Everton. Akumin Inc. rose after an agreement with Stonepeak to go private. Textainer Group Holdings Limited gained after agreeing to be acquired by Stonepeak. Harpoon Therapeutics, Inc. climbed after disclosing updated interim data from a clinical trial. Roivant Sciences Ltd. rose after Roche agreed to acquire Telavant. Troika Media Group, Inc. fell after reporting financial results. XORTX Therapeutics Inc. dipped after a significant jump on Friday.

Portfolio Pulse from Lisa Levin

October 23, 2023 | 11:32 am

BGS

NUS

WBA

Three high-yielding dividend stocks in the consumer staples sector have been highlighted by Wall Street's most accurate analysts. These include Walgreens Boots Alliance, Inc. (WBA) with a dividend yield of 9.03%, B&G Foods, Inc. (BGS) with a yield of 8.97%, and Nu Skin Enterprises, Inc. (NUS) with a yield of 8%. Recent news for these companies include a settlement by WBA, an upsized offering by BGS, and upbeat Q2 earnings for NUS.

Portfolio Pulse from Lisa Levin

October 23, 2023 | 11:32 am

ALZN

Alzamend Neuro Inc (NASDAQ:ALZN) has submitted an investigational new drug (IND) application to the FDA for a Phase IIA clinical study of AL001 for the treatment of major depressive disorder (MDD). AL001 is a novel lithium-delivery system that could deliver the benefits of marketed lithium salts while mitigating associated toxicities. The company aims to start a Phase IIA study following the FDA's approval. ALZN shares are down 0.55% at $0.20 premarket.

Portfolio Pulse from Akanksha Bakshi

October 23, 2023 | 11:31 am

AMZN

GOOGL

META

MSFT

TSLA

The new trading week is expected to face challenges due to earnings concerns, fears of rate hikes, and geopolitical tensions. Major corporations including Alphabet, Microsoft, Meta Platforms, and Amazon are set to release their earnings reports this week. Surging bond yields are expected to unsettle investors as the yield on the 10-year Treasury note has surpassed 5%. Last week, major stock indices experienced a decline due to robust economic data driving bond yields higher. The release of disappointing earnings reports, including that of Tesla, compounded concerns about corporate profit growth.

Portfolio Pulse from Shanthi Rexaline

October 23, 2023 | 11:27 am

ELS

B of A Securities analyst Jeffrey Spector has downgraded Equity Lifestyle Props (NYSE:ELS) from Buy to Neutral and lowered the price target from $70 to $64.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:23 am

VERV

Verve Therapeutics has received clearance from the FDA for its Investigational New Drug application for VERVE-101 in patients with heterozygous familial hypercholesterolemia. This has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:22 am

HARP

Harpoon Therapeutics has announced a private placement of up to $150 million. The funds will be used to advance the company's pipeline of T cell engagers.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:19 am

SHAK

Barclays analyst Jeffrey Bernstein has maintained an Equal-Weight rating on Shake Shack (NYSE:SHAK) and lowered the price target from $72 to $59.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:18 am